Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center,Randomized,Double-blind Phase II Study to Evaluate the Efficacy and Safety of LP-003 in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment

NCT06228560 is registered in ClinicalTrials.gov with Longbio Pharma as lead sponsor.

NCT NCT06228560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06228560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center,Randomized,Double-blind Phase II Study to Evaluate the Efficacy and Safety of LP-003 in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
Lead sponsor
Longbio Pharma
Phase
Phase 2
Overall status
Completed
Start date
January 26, 2024
Completion date
November 14, 2025
Enrollment
202 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

chronic spontaneous urticaria